interleukin-1beta-converting enzyme inhibitor

encoded by the crmA gene (cytokine response modifier gene); prevents the proteolytic activation of IL-1, thereby suppressing an IL-1beta response to infection; amino acid sequence has been determined; cytokine response modifier A a strategically deployed viral weapon

Also Known As:

Crma protein; Crma protein, Cowpox virus; ICE-I protein; IL-1-CEI; IL-1beta converting enzyme inhibitor; SPI-2 cysteine proteinase inhibitor; SPI-2 protein, Cowpox virus; Serp-2 protein, Cowpox virus; caspase-1 inhibitor; cytokine response modifier protein, Cowpox virus; hemorrhage-inducing 38 kDa protein, Cowpox virus; serine proteinase inhibitor 2 protein, Cowpox virus

Networked: 90 relevant articles (9 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chen, Zhong: 3 articles (11/2022 - 01/2020)
2.	Wang, Yi: 3 articles (11/2022 - 01/2020)
3.	Alvarez, Diego F: 3 articles (10/2018 - 10/2016)
4.	Audia, Jonathon P: 3 articles (10/2018 - 10/2016)
5.	Chaudry, Irshad H: 3 articles (05/2007 - 05/2005)
6.	Choudhry, Mashkoor A: 3 articles (05/2007 - 05/2005)
7.	Li, Xiaoling: 3 articles (05/2007 - 05/2005)
8.	Hu, Gang: 2 articles (11/2022 - 01/2020)
9.	Li, Yan: 2 articles (02/2022 - 08/2020)
10.	Wang, Yi-Hao: 2 articles (02/2022 - 08/2020)

Related Diseases

1.	Brain Edema (Cerebral Edema) 09/13/2017 - "Administration of AC-YVAD-CMK, a caspase-1 inhibitor, reduced the expression of IL-1β and IL-18 and the number of PI-positive cells, attenuated brain edema, and improved neurological function, which was also observed in fluoxetine-treated rats. " 01/01/2021 - "(3) NLRP3 inflammasome inhibitor MCC950, caspase-1 inhibitor VX-765 and IL-1β inhibitor diacerein attenuated brain edema, minimized hemorrhagic transformation and improved neurological outcome, demonstrating the roles of NLRP3 inflammasome in the hyperglycemia-mediated HT and poor outcome in the ischemic stroke rats with acute hyperglycemia. "
2.	Autoimmune Diseases (Autoimmune Disease) 06/14/2015 - "Our results suggest that caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate DC IL-1-IL-17 pathway and provides new evidence that caspase-1 is an important drug target in the treatment of MG and other autoimmune diseases." 08/24/2017 - "These results suggest that caspase-1 inhibitor ameliorates EAMG by regulating humoral immune response, thus providing new insights into the development of myasthenia gravis and other autoimmune diseases therapies."
3.	Atherosclerosis 01/01/2020 - "Here we investigated the effect of caspase-1 inhibitor VX-765 on atherosclerosis and vascular smooth muscle cells (VSMCs) pyroptosis. " 01/01/2021 - "VX765, a specific caspase-1 inhibitor, has been shown to have a protective effect against several diseases including sepsis, atherosclerosis, and glial inflammatory disease. " 01/01/2023 - "The current study investigated the therapeutic effects of inhibition of GSDMD activation by the novel GSDMD inhibitor N-Benzyloxycarbonyl-Leu-Leu-Ser-Asp(OMe)-fluoromethylketone (Z-LLSD-FMK), the specific caspase-1 inhibitor N-Benzyloxycarbonyl-Tyr-Val-Ala-Asp(OMe)-fluoromethylketone (Z-YVAD-FMK), and a combination of both on atherosclerosis in ApoE-/- mice fed a western diet at 5 weeks of age, and further determined the efficacy of these polypeptide inhibitors in bone marrow-derived macrophages (BMDMs). "
4.	Cognitive Dysfunction 04/09/2021 - "Publisher Correction: Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging." 11/01/2020 - "Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging." 01/01/2019 - "Caspase-1 inhibitor exerts brain-protective effects against sepsis-associated encephalopathy and cognitive impairments in a mouse model of sepsis." 10/19/2021 - "In addition, the NLRP3 inhibitor MCC950 or the caspase-1 inhibitor VX-765 was used to investigate the role of the NLRP3/caspase-1 axis in ketamine-induced neurotoxicity and cognitive dysfunction. " 01/01/2020 - "We found that FSK and STZ significantly increased the hyperphosphorylated tau level, pyroptosis-related protein in PC12 cell and rats' brain, and inhibited the activity of caspase-1 by caspase-1 inhibitor, caspase-1 siRNA, or incubated with Interleukin(IL)-1β/IL-18 neutralizing antibody could notably alleviate the FSK and STZ induced PC12 cells damage and improve the cognitive disorder in ICV-FSK and ICV-STZ rats. "
5.	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 06/14/2015 - "Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway." 12/01/2023 - "Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia gravis through targeting macrophages." 08/24/2017 - "Caspase-1 inhibitor regulates humoral responses in experimental autoimmune myasthenia gravis via IL-6- dependent inhibiton of STAT3." 06/14/2015 - "Our results suggest that caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate DC IL-1-IL-17 pathway and provides new evidence that caspase-1 is an important drug target in the treatment of MG and other autoimmune diseases." 06/14/2015 - "To investigate the effects of caspase-1 inhibitor on experimental autoimmune myasthenia gravis (EAMG), an animal model of MG, caspase-1 inhibitor was administered to Lewis rats immunized with region 97-116 of the rat AChR α subunit (R97-116 peptide) in complete Freund's adjuvant. "

Related Drugs and Biologics

1.	belnacasan
2.	N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone
3.	Peptides (Polypeptides)
4.	benzyloxycarbonyltyrosyl- valyl- alanyl- aspartic acid fluoromethyl ketone
5.	alanylaspartic acid
6.	Therapeutic Uses
7.	Apolipoproteins E (ApoE)
8.	leucylleucine (Leu-Leu)
9.	Inflammasomes
10.	Interleukin-18 (Interleukin 18)

Related Therapies and Procedures

1.	Therapeutics
2.	Intraperitoneal Injections
3.	Ligation
4.	Spinal Injections
5.	Intranasal Administration